• PDF / 167,978 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 81 Downloads / 159 Views

DOWNLOAD

REPORT

173-5503/20/0866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866

1

Recommend Documents

Dapagliflozin cost effective for HF with reduced ejection fraction

147 23 184KB

Heart Failure with Reduced Ejection Fraction (HFrEF)

159 16 35MB

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?

197 65 520KB

Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HF

148 32 545KB

Which oesophageal cancer screening strategy is cost effective in China?

144 60 163KB

Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction

179 56 749KB

Avoiding breaks with bisphosphonates is cost effective

196 9 124KB

Heart Failure with Preserved Ejection Fraction (HFpEF)

169 39 35MB

Does heart failure with mid-range ejection fraction resemble heart failure with preserved ejection fraction?

157 26 342KB

Physiological benefits evaluated by quantitative flow ratio in patients with reduced left ventricular ejection fraction

153 22 1MB

Capecitabine + irinotecan cost effective for colorectal cancer in China

154 88 163KB

Benefits and adverse effects of ACE inhibitors in patients with heart failure with reduced ejection fraction: a systemat

156 44 2MB